Repligen

RGEN

Market cap $9.36B

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participate in the 8th Annual Evercore Healthcare Conference, being held December 2 -4 in Coral Gables, Florida. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on December 3rd at 1:20 p.m. ET.

Repligen Corporation ( RGEN ) 7th Annual Wolfe Research Healthcare Conference November 18, 2025 12:40 PM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Steven Chehames Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC All right. Good afternoon, everybody.

Repligen Corporation ( RGEN ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Matthew Stanton - Jefferies LLC, Research Division Presentation Matthew Stanton Jefferies LLC, Research Division Thanks. My name is Matt Stanton.

Repligen stands out as a leading bioprocess supplier, benefiting from secular growth in biologics and industry patent expirations. RGEN's strong balance sheet, recurring organic growth, and strategic acquisitions position it for continued outperformance despite sector volatility. The current depressed valuation and stable financials make RGEN attractive for long-term investors seeking bioprocessing exposure.

Repligen Corporation ( RGEN ) Stifel 2025 Healthcare Conference November 11, 2025 10:00 AM EST Company Participants Olivier Loeillot - President, CEO & Director Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Daniel Arias Stifel, Nicolaus & Company, Incorporated, Research Division I'm wrapping up the quarter for a lot of these sessions. As a kickoff, for Repligen, it was a good quarter.

Repligen Corporation ( RGEN ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Jacob Johnson - Vice President of Investor Relations Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. With that, we're ready to kick things off.

Repligen posts strong Q3 results with revenue growth and an earnings beat, yet shares dip as tighter EPS guidance tempers investor optimism.

Repligen Corporation (NASDAQ:RGEN ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Jacob Johnson Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Daniel Arias - Stifel, Nicolaus & Company, Incorporated, Research Division Daniel Leonard - UBS Investment Bank, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Douglas Schenkel - Wolfe Research, LLC Puneet Souda - Leerink Partners LLC, Research Division Steven Etoch - Stephens Inc., Research Division Casey Woodring - JPMorgan Chase & Co, Research Division Daniel Markowitz - Evercore ISI Institutional Equities, Research Division Brendan Smith - TD Cowen, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Tom DeBourcy - Nephron Research LLC Luke Sergott - Barclays Bank PLC, Research Division Brandon Couillard - Wells Fargo Securities, LLC, Research Division Presentation Operator Thank you for standing by.

Repligen (RGEN) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.43 per share a year ago.

WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter of 2025, covering the three- and nine- month periods ended September 30, 2025. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2025 and access information for today's webcast and conference call.